Simplexia launches CEO search as it secures bridge funding to complete clinical preparations

Simplexia AB has secured additional funding to complete key preparatory activities leading up to the first clinical study in patients. This funding covers necessary toxicology studies and other initial steps, while the company continues efforts to secure full financing for the clinical program. The planned study is a Phase 1/2 trial scheduled to begin in the end of 2026.

“We are very pleased to have secured the funds necessary to conduct the required toxicology studies and prepare for our first clinical trial in patients. There is currently no cure or vaccine for genital herpes, and this funding takes us an important step closer to our goal of developing a preventive and therapeutic vaccine,” says Lena Degling Wikingsson, Chairman of the Board.

To support this next phase of growth, Simplexia has initiated the search for a CEO with extensive experience in financing and a strong investor network. Until a new CEO is appointed, Nina Lindblom, PhD, from the Karolinska Institute, will serve as Deputy CEO. Nina has been a member of the Simplexia Board since 2021 and has also been actively involved in the company’s operational activities.

The Board would like to thank Tim Wood for his service and commitment as CEO of Simplexia, which has been a major contributor to Simplexia being in this exciting development phase.